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A 44-year-old man who had been working in a glass washing
factory visited our hospital with cough, sputum, and dyspnea after
accidental exposure to hydroﬂuoric acid of 50% concentration 10
days ago.
He was ex-smoker who quit smoking 10 years ago and had 5
pack years smoking history. He had usually been working in the
glass washing factory in position of ofﬁce based job. At this time
he was exposed to 50% concentration of HF during opening of cap
of HF bottle. After opening for approximately 1e2 min, he experi-
enced a burning sensation in his eyes, nose, and mouth and he
developed chest tightness and dyspnea. He had persistent prob-
lems on breathing for previous 10 days, and he ﬁnally came to
hospital.
His initial blood pressure was 130/70 mmHg, pulse rate 70/min,
respiratory rate 20/min, and body temperature 36.8 C. There were
no abnormal ﬁndings in physical examinations. Chest radiography
and PNS water's view showed normal ﬁndings. White blood cell
count was 9590 cells/mL (neutrophil, 65.1%; lymphocyte, 24.5%;
monocyte, 8.6%; eosinophil, 1.5%) and other laboratory measure-
ments were within normal ranges. Measuring bronchodilator
response with pulmonary function test was done; FEV1/FVC 89%;
FVC 5.10L (101%); FEV1 4.56L (121%). He showed positive reaction
to Dermatophagoides farinae and Dermatophagoides pteronyssinus
on allergen skin prick test. A non-speciﬁc bronchial challenge test
with methacholine was performed to evaluate airway hyperres-
ponsiveness and the result was positive (PC20 ¼ 7.78 mg/ml).
HF (hydroﬂuoric acid) is a weak acid and is colorless, potent res-
piratory irritant with an unpleasant odor.1,2 The boiling point of
anhydrous HF is 19.5 C and it is miscible with water, and HF fumes
strongly in moist air.2 The odor threshold is reported to be
0.5e3.0 parts per million.2 HF is a toxic substance used widely in
both industrial and domestic settings, and is used to produce a va-
riety of chemicals and in numerous industrial processes.1,2 It is most
largely used in production of ﬂuorocarbon compounds.2 HF is
unique among acids because its toxicity is mostly attributed to an
anion and ﬂuoride, not to a cation and a hydrogen ion responsible
for toxicity in many other acids.2 Most acids cause burns and necro-
sis from liberated hydrogen ions. Generally, HF is produced by the
reaction of sulfuric acid with calcium ﬂuoride.2
HF is strong irritant to eyes, nose, throat, and skin. HF causes var-
iable symptoms tears, eye redness, rhinorrhea, sore throat, cough,
headache, and dermatalgia.1,3,4 Even in cases in which noPeer review under responsibility of Japanese Society of Allergology.
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dyspnea, cyanosis, and pulmonary edema may occur later.1 There
are few reports of adverse health effects from inhalation exposure
to a consumer product containing HF. One report described a single
case of chemical pneumonitis and adult respiratory distress syn-
drome following household use of an HF-containing rust stain
remover. Another reported a case of adult-onset asthma immedi-
ately following use of the same household rust stain remover.4
Reactive airways dysfunction syndrome (RADS), or irritant
induced asthmawithout latency, is characterized by the immediate
onset of asthma following a single exposure (or possibly several ex-
posures) to irritating vapor, fume, or smoke.5e7
RADSwas originally described by Brooks and Lockers5 in 1981 as
sudden onset of non-immunological asthma resulting from an
exposure to high-level irritant gases. Many cases occurred after
the 9/11 collapse of the New York World Trade Center, resulting
from the inhalation of fumes and particulate matters.8 Symptoms
persist for at least 12 weeks but there is no previously documented
evidence of asthma or other chronic lung disease.8
According to ACCP9 RADS can be diagnosed by following condi-
tions: (1) A documented absence of preceding respiratory com-
plaints; (2) Onset of symptoms after a single exposure incident;
(3) Exposure to very high concentrations of a mixture of sodium hy-
pochlorite and hydrochloric acid; (4) Onset of symptoms within
24 h after the exposure, with persistence of symptoms for at least
12 weeks; (5) Symptoms simulating asthma with cough, wheeze,
and dyspnea; (6) Presence of airﬂow obstruction; and (7) Absence
of all other pulmonary diseases. RADS is also a subcategory of
irritant-induced occupational asthma (OA), and irritant-induced
OA can be classiﬁed by exposure concentration and duration of
exposure.8,10 RADS is characterized by extremely high exposure
concentration which is over occupational exposure limit and the
duration of exposure is below one day.8,10
The patient described in this report developed adult onset
asthma based on his history of symptoms, dyspnea improvement
with inhaled steroid medication, and the positive tests for non-
speciﬁc bronchial hyperreactivity. His asthma had immediate onset
following the exposure of high concentration of HF, and the symp-
toms had persisted for at least 3 months. Therefore, based on the
history and medical ﬁndings he appears to be suitable for the
criteria for RADS. In conclusion, we report a 44-year old man
with RADS including bronchial asthma with cough, sputum, and
dyspnea after exposure to high concentration of hydroﬂuoric acid.
He was educated from avoiding exposure of HF, and now well
controlled treated with normal lung function by step downing
inhaled steroids.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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